FUNPLUS
28.10.2021 17:02:10 CEST | Business Wire | Press release
FunPlus, a leading independent mobile game developer and publisher, announced today that Ben Cousins has been appointed Head of Studio Operations, supervising projects in development at FunPlus’ studios in Moscow and Stockholm. Based in Stockholm, and in close collaboration with studio leadership in both locations, Cousins will help to optimize the studios’ working environment and align all studio activities to contribute to successful product development and continued company growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005417/en/
A game industry thought leader, Cousins created Battlefield Heroes , one of the western world’s first free-to-play games. A former Executive Producer of the Battlefield franchise at DICE, he has also led the development of other innovative games services on PC, console and mobile at DeNA, Sony Computer Entertainment and others. In recent years he has been working as an independent consultant for leading games-as-a-service companies.
“FunPlus continues to attract top-notch talent, and Ben brings a wealth of expertise that will contribute to the creative excellence of our teams,” said Chris Petrovic, Chief Business Officer of FunPlus. “As a pioneer in the free-to-play space, and with extensive experience working with numerous developers, I am confident that FunPlus’ ambitious projects will flourish under his supervision.”
FunPlus, which is headquartered in Switzerland, has grown its European presence steadily over the past three years, with the opening of studios in Stockholm and Moscow, as well as its publishing office in Barcelona.
For more information on FunPlus, visit http://www.FunPlus.com . Find a link to assets here
About FunPlus
Founded in 2010, FunPlus is a world class, independent game developer and publisher headquartered in Switzerland with operations in Spain, Sweden, Russia, United States, Singapore, Japan, and China. As an organization that fosters the best creative talent in the world and employs nearly 2,000 people, the company has developed and published mobile games that have ranked in the #1 spot in nearly 70 countries, which includes State of Survival , King of Avalon , and Guns of Glory . FunPlus studios include KingsGroup, Puzala, Seven Games, and Imagendary Studios, each part of a growing global network of developers working on unique brands of staple genres including strategy, puzzle, and role-playing games.
As the top publisher in the 4X strategy category for 3 years in a row, FunPlus has leveraged this success to bring the worlds of gaming and mainstream entertainment together through successful collaborations with top tier IP such as AMC’s The Walking Dead , which is currently live in the company’s biggest game, State of Survival .
The FunPlus brand powers FunPlus Phoenix (FPX), one of the world’s most successful esports organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005417/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom